metformin + glibenclamide

Metformin + glibenclamide is an oral fixed-dose combination therapy developed and marketed by Reyoung Pharmaceutical for the management of type 2 diabetes mellitus. This medication combines two antihyperglycemic agents with complementary mechanisms: metformin, a biguanide, and glibenclamide (also known as glyburide), a second-generation sulfonylurea. Metformin works primarily by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues, while glibenclamide stimulates the release of insulin from pancreatic beta cells by binding to ATP-sensitive potassium channels. This dual approach addresses both insulin resistance and secretory dysfunction, providing a potent glucose-lowering effect in patients whose glycemic levels are inadequately controlled by monotherapy or lifestyle interventions. In China, Reyoung Pharmaceutical's version is approved and typically administered as a capsule.

Brand names

Metformin Glibenclamide Capsules

Other names

二甲双胍格列本脲胶囊metformin + glyburideMetformin Glibenclamide